Lario Therapeutics Limited, a biopharmaceutical company developing first-in-class precision medicines targeting disease-modifying treatments for severe neurological disorders.
Acousia Therapeutics GmbH, a clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss.
Golgi Neurosciences is a company-creator boutique with one ambitious mission: setting the ground to create therapies for the treatment of devasting neurodegenerative diseases by applying rigorously “Grounded Objectives Leading to a Great Impact (GOLGI)”.
Golgi Neurosciences S.r.l.
Kunzi Campus - via Ariosto, 19
20091 Bresso (Milan, Italy)
Share capital: 430.815 euro
C.F./P.IVA/VAT: 12596130968
Numero REA: MI-2671780
Copyright © 2026 Golgi Neurosciences. All rights reserved | Privacy Policy | Cookie Policy | Disclaimer